A detailed history of Jump Financial, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 31,060 shares of LCTX stock, worth $52,802. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,060
Holding current value
$52,802
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025

BUY
$0.39 - $1.13 $12,113 - $35,097
31,060 New
31,060 $28,000
Q1 2024

May 13, 2024

BUY
$0.86 - $1.48 $62,650 - $107,816
72,849 New
72,849 $107,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $289M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.